Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).

Date publication

juillet 2026

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FUMET Jean-David , Dr EBERST Lauriane

Tous les auteurs :
Kabirian R, de Saint Ghislain M, Le Saux O, Mathiot L, Frenel JS, Augereau P, Forestier A, Fumet JD, Eberst L, Quesada S, Kalbacher E, Lescure C, De La Motte Rouge T, Grau Bejar JF, Barraud S, Genevee T, Bello Roufai D, Rodrigues M, Leary A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42538280

Résumé

Immune checkpoint inhibitors have significantly improved the outcome of patients with cervical and endometrial cancers but the benefit of immune checkpoint inhibitor rechallenge is unknown. We aimed to evaluate the efficacy and safety of immune checkpoint inhibitor rechallenge in this population.

Mots clés

Cervical Cancer, Endometrial Cancer, Gynecology, Immune Checkpoint Inhibitors, Immunotherapy, Rechallenge

Référence

Int J Gynecol Cancer. 2026 07 15;:104867